Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2021-12-03 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于修改《公司章程》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding amendments to the company's Articles of Association (公司章程) due to changes in registered capital and total shares. It references board resolutions and regulatory compliance but does not contain financial statements or detailed financial data. The document is relatively short (1210 characters) and serves as a formal notice of corporate governance changes related to capital structure and company bylaws. It is not a full annual report, interim report, or financial supplement. It is also not a proxy solicitation or voting results announcement. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about corporate governance changes without detailed financial data or report attachments.
2021-12-03 Chinese
哈药集团股份有限公司关于所属企业药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a specific pharmaceutical product passing a regulatory evaluation (仿制药一致性评价) by the National Medical Products Administration (国家药品监督管理局). It details the drug's specifications, regulatory approval, market impact, and risk warnings. The document is short (1357 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an announcement of a regulatory approval event related to the company's product, not a financial report or management discussion. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about product approval and market impact, best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-11-29 Chinese
哈药集团股份有限公司关于收到部分征收补偿款的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding the receipt of partial compensation for property expropriation. It references a board meeting resolution and details about the compensation amount received and expected accounting treatment. The document is short (690 characters) and serves as a formal notification of a specific event related to asset compensation, not a full financial report or audit. It does not contain comprehensive financial statements or detailed analysis. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2021-10-29 Chinese
哈药集团股份有限公司2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第三季度报告' which translates to '2021 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on accounting policies. The report covers the third quarter period and includes unaudited financial statements. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. There is no indication that this is an announcement of a report or a certification document, and the length (over 14,000 characters) supports it being a full report rather than a brief announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2021
2021-10-25 Chinese
哈药集团股份有限公司关于政府征收部分房屋资产的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement by 哈药集团股份有限公司 regarding the government's expropriation of certain property assets owned by the company. It details the compensation amount, the nature of the transaction, and its expected impact on the company's financials. The document is relatively short (1289 characters) and serves as a formal disclosure of a specific event affecting the company’s assets and financial position. It does not contain comprehensive financial statements or detailed financial performance data, nor is it a report or presentation. It is a regulatory announcement about a specific transaction and its impact, fitting best under the category of Regulatory Filings (RNS).
2021-10-18 Chinese
哈药集团股份有限公司九届十五次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. regarding the approval of a compensation agreement for government expropriation of certain company property. It includes details about the board meeting, voting results, and the expected financial impact. The document is an official announcement of a board decision rather than a full report or financial statement. It does not contain comprehensive financial data or detailed management discussion. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on a specific board decision, not a full report or regulatory filing.
2021-10-18 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.